Sugi Predict

Sugi Predict / Compounds / SCHEMBL1889385

SCHEMBL1889385

SCHEMBL1889385

CC(C)(C)OC(=O)N1CCC(Oc2ccccc2C=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.54
▸ GPR119 Q8TDV5 10/20 0.51
▸ PDE4B Q07343 3/20 0.50
▸ PDE4D Q08499 3/20 0.50
▸ PDE4A P27815 2/20 0.50
▸ PDE4C Q08493 2/20 0.50
▸ PTPN2 P17706 1/20 0.47
▸ PTPN1 P18031 1/20 0.47
▸ PTPN6 P29350 1/20 0.47
▸ CACNB4 O00305 1/20 0.47
▸ CACNA1A O00555 1/20 0.47
▸ CACNA1G O43497 1/20 0.47
▸ CACNG3 O60359 1/20 0.47
▸ CACNA1F O60840 1/20 0.47
▸ CACNA1H O95180 1/20 0.47
▸ CACNB3 P54284 1/20 0.47
▸ CACNA2D1 P54289 1/20 0.47
▸ CACNG7 P62955 1/20 0.47
▸ CACNA1B Q00975 1/20 0.47
▸ CACNA1D Q01668 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1894331 0.93 USP30 (0.50) KDM1AGPR119PDE4BPDE4DPDE4A
SCHEMBL3250796 0.89 KDM1A (0.53) KDM1AGPR119PDE4BPDE4DPDE4A
SCHEMBL15058534 0.88 USP30 (0.46) KDM1AGPR119PDE4BCACNB4CACNA1A
SCHEMBL8327398 0.84 L3MBTL1 (0.49) PDE4BKDM4E
SCHEMBL3157462 0.84 PDE4B (0.49) KDM1AGPR119PDE4BPDE4DPDE4A
SCHEMBL274655 0.84 PDE4B (0.52) KDM1AGPR119PDE4BPDE4DPDE4A
SCHEMBL2420719 0.84 PDE4B (0.52) KDM1AGPR119PDE4BPDE4DPDE4A
SCHEMBL275205 0.84 PDE4B (0.52) KDM1AGPR119PDE4BPDE4DPDE4A
SCHEMBL19839235 0.84 PDE4B (0.64) KDM1AGPR119PDE4BPDE4DPDE4A
SCHEMBL21765007 0.84 KDM1A (0.57) KDM1AGPR119PDE4BPDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4545515-A1 BCL-2 INHIBITORS BeiGene Switzerland GmbH (CH) 2025-04-30 — — EP disclosed
US-20240376104-A1 Bcl-2 Inhibitors BEIGENE LTD. (KY) 2024-11-14 — — US disclosed
US-12077536-B2 BCL-2 inhibitors BEIGENE, LTD. (KY) 2024-09-03 — — US disclosed
CN-117683029-A Bcl-2 inhibitors 百济神州有限公司 2024-03-12 — — CN disclosed
CN-117430601-A Bcl-2 inhibitors 百济神州有限公司 2024-01-23 — — CN disclosed
CN-112437772-B Bcl-2 inhibitors 百济神州有限公司 2023-11-21 — — CN disclosed
US-20220402915-A1 BCL-2 INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-12-22 — — US disclosed
US-11420968-B2 Bcl-2 inhibitors BEIGENE, LTD. (KY) 2022-08-23 — — US disclosed
EP-3788042-A1 BCL-2 INHIBITORS BeiGene, Ltd. (KY) 2021-03-10 — — EP disclosed
CN-112437772-A Bcl-2 inhibitors 百济神州有限公司 2021-03-02 — — CN disclosed
EP-2315763-B1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-06-01 — — EP disclosed
EP-2315763-B1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-06-01 — — EP disclosed
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2015-02-26 — — US disclosed
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2015-02-26 — — US disclosed
US-8846947-B2 Benzimidazoles and related analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2014-09-30 — — US disclosed
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-05-26 — — US disclosed
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-05-26 — — US disclosed
EP-2315763-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-05-04 — — EP disclosed
WO-2010003048-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-01-07 — — WO disclosed
WO-2010003048-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402915-A1 BCL-2 INHIBITORS BCL2, BCL2L1, BCL2L2 KDM1A 2400/4885GPR119 653/4885PDE4B 2805/4885
US-11420968-B2 Bcl-2 inhibitors BCL2, BCL2L1, BCL2L2 KDM1A 2400/4885GPR119 653/4885PDE4B 2805/4885
US-12077536-B2 BCL-2 inhibitors BCL2, BCL2L1, BCL2L2 KDM1A 2400/4885GPR119 653/4885PDE4B 2805/4885
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 KDM1A 781/4885GPR119 165/4885PDE4B 1786/4885
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 KDM1A 779/4885GPR119 137/4885PDE4B 1821/4885
US-20240376104-A1 Bcl-2 Inhibitors BCL2, BCL2L1, BCL2L2 KDM1A 2400/4885GPR119 653/4885PDE4B 2805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.